Get the Stockscreener App
43.48
0.51%
0.22
Pre-market:
43.91
0.43
+0.99%
Kymera Therapeutics Inc stock is traded at $43.48, with a volume of 493.70K.
It is up +0.51% in the last 24 hours and up +7.04% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$43.26
Open:
$43.46
24h Volume:
493.70K
Relative Volume:
0.68
Market Cap:
$3.11B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-14.03
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+6.86%
1M Performance:
+7.04%
6M Performance:
+32.20%
1Y Performance:
-5.97%
1-Day Range:
$43.11
$44.43
1-Week Range:
$40.10
$44.43
52-Week Range:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
43.48 | 3.09B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics (NASDAQ:KYMR) Trading Up 5.7%Here's What Happened - MarketBeat
Walleye Capital LLC Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Published on: 2025-09-08 14:53:27 - beatles.ru
Kymera Therapeutics, Inc. $KYMR Shares Sold by Cinctive Capital Management LP - MarketBeat
Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories? - ca.finance.yahoo.com
Is Kymera Therapeutics Inc. reversing from oversold territoryDay Trade & Safe Capital Preservation Plans - Newser
Will Kymera Therapeutics Inc. outperform tech stocksJuly 2025 Reactions & Community Consensus Trade Signals - 뉴스영
Signal strength of Kymera Therapeutics Inc. stock in tech scannersWeekly Investment Report & Growth Focused Stock Reports - Newser
What is the PEG ratio of Kymera Therapeutics Inc.July 2025 WrapUp & Growth Focused Stock Reports - خودرو بانک
Is Kymera Therapeutics Inc. forming a breakout patternJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - خودرو بانک
Kymera Therapeutics Inc. stock trendline breakdownPortfolio Value Report & Stock Portfolio Risk Control - Newser
Institutional scanner results for Kymera Therapeutics Inc.Earnings Growth Summary & Stock Portfolio Risk Control - Newser
What candlestick patterns are forming on Kymera Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - Newser
Is Kymera Therapeutics Inc. stock poised for growth2025 Bull vs Bear & Daily Entry Point Trade Alerts - Newser
Will Kymera Therapeutics Inc. stock recover after recent dropPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about Kymera Therapeutics Inc.2025 Market Outlook & Real-Time Market Trend Scan - Newser
What’s the outlook for Kymera Therapeutics Inc.’s sectorMarket Rally & AI Powered Market Entry Strategies - خودرو بانک
Can technical indicators confirm Kymera Therapeutics Inc.’s reversalQuarterly Profit Summary & Daily Volume Surge Signals - Newser
Should I trade or invest in Kymera Therapeutics Inc.2025 Risk Factors & Stepwise Trade Signal Guides - خودرو بانک
Kymera Therapeutics Announces New Chief Legal Officer - The Globe and Mail
Is Kymera Therapeutics Inc. a play on infrastructure spendingIndex Update & Real-Time Market Sentiment Alerts - خودرو بانک
Yiheng Capital Management L.P. Makes New $3.36 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Sentiment analysis tools applied to Kymera Therapeutics Inc.July 2025 Outlook & High Accuracy Trade Alerts - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. reboundEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Real time social sentiment graph for Kymera Therapeutics Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Will Kymera Therapeutics Inc. stock recover after earnings2025 Support & Resistance & Daily Stock Trend Reports - خودرو بانک
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - citybiz
Kymera Therapeutics Presents at Citi's 2025 Biopharma Back to School Conference - AInvest
Kymera Names Adams Chief Legal Officer, Corporate Secretary - Bloomberg Law News
Kymera Therapeutics shares rise 2.08% intraday after appointing Brian Adams as Chief Legal Officer. - AInvest
Former Relay Therapeutics CLO Brian Adams Joins Immunology Pioneer Kymera as Legal Chief and Secretary - Stock Titan
Chart overlay techniques for tracking Kymera Therapeutics Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - Newser
Aug Movers: Can Kymera Therapeutics Inc. keep up with sector leaders2025 Market Trends & Short-Term High Return Ideas - خودرو بانک
Kymera Therapeutics Inc. stock outlook for YEAR2025 Retail Activity & Reliable Trade Execution Plans - Newser
How sensitive is Kymera Therapeutics Inc. to inflation2025 Market Trends & Low Risk Growth Stock Ideas - خودرو بانک
Real time breakdown of Kymera Therapeutics Inc. stock performanceTrade Entry Report & Low Drawdown Momentum Trade Ideas - Newser
Visual trend scoring systems applied to Kymera Therapeutics Inc.2025 Momentum Check & Verified High Yield Trade Plans - Newser
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | KYMR Stock News - GuruFocus
Market Fear: What’s the outlook for Kymera Therapeutics Inc.’s sectorTrade Exit Report & Fast Exit/Entry Strategy Plans - خودرو بانک
Trendlines Suggest Kymera Therapeutics Inc. May Bottom Out SoonVolume Spike & Weekly Breakout Opportunity Watchlist - beatles.ru
How liquid is Kymera Therapeutics Inc. stockJuly 2025 Patterns & AI Powered Trade Plan Recommendations - خودرو بانک
Using data models to predict Kymera Therapeutics Inc. stock movementRecession Risk & Low Risk Entry Point Tips - Newser
How to escape a deep drawdown in Kymera Therapeutics Inc.2025 Volume Leaders & Real-Time Volume Analysis - Newser
Can Kymera Therapeutics Inc. rally from current levels2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):